Medical Care
Global Metastatic Cancer Drug Market Research Report 2024
- Aug 28, 24
- ID: 515363
- Pages: 96
- Figures: 186
- Views: 3
Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms.
The global Metastatic Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Metastatic Cancer Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metastatic Cancer Drug.
Report Scope
The Metastatic Cancer Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metastatic Cancer Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metastatic Cancer Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
Segment by Type
Trastuzumab
Pertuzumab
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metastatic Cancer Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Metastatic Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Metastatic Cancer Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metastatic Cancer Drug.
Report Scope
The Metastatic Cancer Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metastatic Cancer Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metastatic Cancer Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
Segment by Type
Trastuzumab
Pertuzumab
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metastatic Cancer Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Cancer Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Trastuzumab
1.2.3 Pertuzumab
1.3 Market by Application
1.3.1 Global Metastatic Cancer Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metastatic Cancer Drug Market Perspective (2019-2030)
2.2 Metastatic Cancer Drug Growth Trends by Region
2.2.1 Global Metastatic Cancer Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metastatic Cancer Drug Historic Market Size by Region (2019-2024)
2.2.3 Metastatic Cancer Drug Forecasted Market Size by Region (2025-2030)
2.3 Metastatic Cancer Drug Market Dynamics
2.3.1 Metastatic Cancer Drug Industry Trends
2.3.2 Metastatic Cancer Drug Market Drivers
2.3.3 Metastatic Cancer Drug Market Challenges
2.3.4 Metastatic Cancer Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metastatic Cancer Drug Players by Revenue
3.1.1 Global Top Metastatic Cancer Drug Players by Revenue (2019-2024)
3.1.2 Global Metastatic Cancer Drug Revenue Market Share by Players (2019-2024)
3.2 Global Metastatic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metastatic Cancer Drug Revenue
3.4 Global Metastatic Cancer Drug Market Concentration Ratio
3.4.1 Global Metastatic Cancer Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Cancer Drug Revenue in 2023
3.5 Metastatic Cancer Drug Key Players Head office and Area Served
3.6 Key Players Metastatic Cancer Drug Product Solution and Service
3.7 Date of Enter into Metastatic Cancer Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metastatic Cancer Drug Breakdown Data by Type
4.1 Global Metastatic Cancer Drug Historic Market Size by Type (2019-2024)
4.2 Global Metastatic Cancer Drug Forecasted Market Size by Type (2025-2030)
5 Metastatic Cancer Drug Breakdown Data by Application
5.1 Global Metastatic Cancer Drug Historic Market Size by Application (2019-2024)
5.2 Global Metastatic Cancer Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metastatic Cancer Drug Market Size (2019-2030)
6.2 North America Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metastatic Cancer Drug Market Size by Country (2019-2024)
6.4 North America Metastatic Cancer Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metastatic Cancer Drug Market Size (2019-2030)
7.2 Europe Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metastatic Cancer Drug Market Size by Country (2019-2024)
7.4 Europe Metastatic Cancer Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metastatic Cancer Drug Market Size (2019-2030)
8.2 Asia-Pacific Metastatic Cancer Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metastatic Cancer Drug Market Size (2019-2030)
9.2 Latin America Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metastatic Cancer Drug Market Size by Country (2019-2024)
9.4 Latin America Metastatic Cancer Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metastatic Cancer Drug Market Size (2019-2030)
10.2 Middle East & Africa Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Metastatic Cancer Drug Introduction
11.1.4 AstraZeneca Revenue in Metastatic Cancer Drug Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Metastatic Cancer Drug Introduction
11.2.4 Merck Revenue in Metastatic Cancer Drug Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Metastatic Cancer Drug Introduction
11.3.4 Pfizer Revenue in Metastatic Cancer Drug Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Celgene
11.4.1 Celgene Company Detail
11.4.2 Celgene Business Overview
11.4.3 Celgene Metastatic Cancer Drug Introduction
11.4.4 Celgene Revenue in Metastatic Cancer Drug Business (2019-2024)
11.4.5 Celgene Recent Development
11.5 AKRON
11.5.1 AKRON Company Detail
11.5.2 AKRON Business Overview
11.5.3 AKRON Metastatic Cancer Drug Introduction
11.5.4 AKRON Revenue in Metastatic Cancer Drug Business (2019-2024)
11.5.5 AKRON Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Metastatic Cancer Drug Introduction
11.6.4 Novartis Revenue in Metastatic Cancer Drug Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Galen
11.7.1 Galen Company Detail
11.7.2 Galen Business Overview
11.7.3 Galen Metastatic Cancer Drug Introduction
11.7.4 Galen Revenue in Metastatic Cancer Drug Business (2019-2024)
11.7.5 Galen Recent Development
11.8 Pacira BioSciences
11.8.1 Pacira BioSciences Company Detail
11.8.2 Pacira BioSciences Business Overview
11.8.3 Pacira BioSciences Metastatic Cancer Drug Introduction
11.8.4 Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2019-2024)
11.8.5 Pacira BioSciences Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Detail
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Metastatic Cancer Drug Introduction
11.9.4 Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2019-2024)
11.9.5 Johnson & Johnson Recent Development
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Detail
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Metastatic Cancer Drug Introduction
11.10.4 Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2019-2024)
11.10.5 Fresenius Kabi AG Recent Development
11.11 Spectrum Pharmaceuticals
11.11.1 Spectrum Pharmaceuticals Company Detail
11.11.2 Spectrum Pharmaceuticals Business Overview
11.11.3 Spectrum Pharmaceuticals Metastatic Cancer Drug Introduction
11.11.4 Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2019-2024)
11.11.5 Spectrum Pharmaceuticals Recent Development
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Detail
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Metastatic Cancer Drug Introduction
11.12.4 Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024)
11.12.5 Takeda Pharmaceutical Recent Development
11.13 Teva Pharmaceutical Industries
11.13.1 Teva Pharmaceutical Industries Company Detail
11.13.2 Teva Pharmaceutical Industries Business Overview
11.13.3 Teva Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.13.4 Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024)
11.13.5 Teva Pharmaceutical Industries Recent Development
11.14 Cipla
11.14.1 Cipla Company Detail
11.14.2 Cipla Business Overview
11.14.3 Cipla Metastatic Cancer Drug Introduction
11.14.4 Cipla Revenue in Metastatic Cancer Drug Business (2019-2024)
11.14.5 Cipla Recent Development
11.15 Sun Pharmaceutical Industries
11.15.1 Sun Pharmaceutical Industries Company Detail
11.15.2 Sun Pharmaceutical Industries Business Overview
11.15.3 Sun Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.15.4 Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024)
11.15.5 Sun Pharmaceutical Industries Recent Development
11.16 Shanghai Fosun Pharmaceutical
11.16.1 Shanghai Fosun Pharmaceutical Company Detail
11.16.2 Shanghai Fosun Pharmaceutical Business Overview
11.16.3 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Introduction
11.16.4 Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024)
11.16.5 Shanghai Fosun Pharmaceutical Recent Development
11.17 Ingenus
11.17.1 Ingenus Company Detail
11.17.2 Ingenus Business Overview
11.17.3 Ingenus Metastatic Cancer Drug Introduction
11.17.4 Ingenus Revenue in Metastatic Cancer Drug Business (2019-2024)
11.17.5 Ingenus Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Cancer Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Trastuzumab
1.2.3 Pertuzumab
1.3 Market by Application
1.3.1 Global Metastatic Cancer Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metastatic Cancer Drug Market Perspective (2019-2030)
2.2 Metastatic Cancer Drug Growth Trends by Region
2.2.1 Global Metastatic Cancer Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metastatic Cancer Drug Historic Market Size by Region (2019-2024)
2.2.3 Metastatic Cancer Drug Forecasted Market Size by Region (2025-2030)
2.3 Metastatic Cancer Drug Market Dynamics
2.3.1 Metastatic Cancer Drug Industry Trends
2.3.2 Metastatic Cancer Drug Market Drivers
2.3.3 Metastatic Cancer Drug Market Challenges
2.3.4 Metastatic Cancer Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metastatic Cancer Drug Players by Revenue
3.1.1 Global Top Metastatic Cancer Drug Players by Revenue (2019-2024)
3.1.2 Global Metastatic Cancer Drug Revenue Market Share by Players (2019-2024)
3.2 Global Metastatic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metastatic Cancer Drug Revenue
3.4 Global Metastatic Cancer Drug Market Concentration Ratio
3.4.1 Global Metastatic Cancer Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Cancer Drug Revenue in 2023
3.5 Metastatic Cancer Drug Key Players Head office and Area Served
3.6 Key Players Metastatic Cancer Drug Product Solution and Service
3.7 Date of Enter into Metastatic Cancer Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metastatic Cancer Drug Breakdown Data by Type
4.1 Global Metastatic Cancer Drug Historic Market Size by Type (2019-2024)
4.2 Global Metastatic Cancer Drug Forecasted Market Size by Type (2025-2030)
5 Metastatic Cancer Drug Breakdown Data by Application
5.1 Global Metastatic Cancer Drug Historic Market Size by Application (2019-2024)
5.2 Global Metastatic Cancer Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metastatic Cancer Drug Market Size (2019-2030)
6.2 North America Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metastatic Cancer Drug Market Size by Country (2019-2024)
6.4 North America Metastatic Cancer Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metastatic Cancer Drug Market Size (2019-2030)
7.2 Europe Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metastatic Cancer Drug Market Size by Country (2019-2024)
7.4 Europe Metastatic Cancer Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metastatic Cancer Drug Market Size (2019-2030)
8.2 Asia-Pacific Metastatic Cancer Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metastatic Cancer Drug Market Size (2019-2030)
9.2 Latin America Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metastatic Cancer Drug Market Size by Country (2019-2024)
9.4 Latin America Metastatic Cancer Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metastatic Cancer Drug Market Size (2019-2030)
10.2 Middle East & Africa Metastatic Cancer Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Metastatic Cancer Drug Introduction
11.1.4 AstraZeneca Revenue in Metastatic Cancer Drug Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Metastatic Cancer Drug Introduction
11.2.4 Merck Revenue in Metastatic Cancer Drug Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Metastatic Cancer Drug Introduction
11.3.4 Pfizer Revenue in Metastatic Cancer Drug Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Celgene
11.4.1 Celgene Company Detail
11.4.2 Celgene Business Overview
11.4.3 Celgene Metastatic Cancer Drug Introduction
11.4.4 Celgene Revenue in Metastatic Cancer Drug Business (2019-2024)
11.4.5 Celgene Recent Development
11.5 AKRON
11.5.1 AKRON Company Detail
11.5.2 AKRON Business Overview
11.5.3 AKRON Metastatic Cancer Drug Introduction
11.5.4 AKRON Revenue in Metastatic Cancer Drug Business (2019-2024)
11.5.5 AKRON Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Metastatic Cancer Drug Introduction
11.6.4 Novartis Revenue in Metastatic Cancer Drug Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Galen
11.7.1 Galen Company Detail
11.7.2 Galen Business Overview
11.7.3 Galen Metastatic Cancer Drug Introduction
11.7.4 Galen Revenue in Metastatic Cancer Drug Business (2019-2024)
11.7.5 Galen Recent Development
11.8 Pacira BioSciences
11.8.1 Pacira BioSciences Company Detail
11.8.2 Pacira BioSciences Business Overview
11.8.3 Pacira BioSciences Metastatic Cancer Drug Introduction
11.8.4 Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2019-2024)
11.8.5 Pacira BioSciences Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Detail
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Metastatic Cancer Drug Introduction
11.9.4 Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2019-2024)
11.9.5 Johnson & Johnson Recent Development
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Detail
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Metastatic Cancer Drug Introduction
11.10.4 Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2019-2024)
11.10.5 Fresenius Kabi AG Recent Development
11.11 Spectrum Pharmaceuticals
11.11.1 Spectrum Pharmaceuticals Company Detail
11.11.2 Spectrum Pharmaceuticals Business Overview
11.11.3 Spectrum Pharmaceuticals Metastatic Cancer Drug Introduction
11.11.4 Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2019-2024)
11.11.5 Spectrum Pharmaceuticals Recent Development
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Detail
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Metastatic Cancer Drug Introduction
11.12.4 Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024)
11.12.5 Takeda Pharmaceutical Recent Development
11.13 Teva Pharmaceutical Industries
11.13.1 Teva Pharmaceutical Industries Company Detail
11.13.2 Teva Pharmaceutical Industries Business Overview
11.13.3 Teva Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.13.4 Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024)
11.13.5 Teva Pharmaceutical Industries Recent Development
11.14 Cipla
11.14.1 Cipla Company Detail
11.14.2 Cipla Business Overview
11.14.3 Cipla Metastatic Cancer Drug Introduction
11.14.4 Cipla Revenue in Metastatic Cancer Drug Business (2019-2024)
11.14.5 Cipla Recent Development
11.15 Sun Pharmaceutical Industries
11.15.1 Sun Pharmaceutical Industries Company Detail
11.15.2 Sun Pharmaceutical Industries Business Overview
11.15.3 Sun Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.15.4 Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024)
11.15.5 Sun Pharmaceutical Industries Recent Development
11.16 Shanghai Fosun Pharmaceutical
11.16.1 Shanghai Fosun Pharmaceutical Company Detail
11.16.2 Shanghai Fosun Pharmaceutical Business Overview
11.16.3 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Introduction
11.16.4 Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024)
11.16.5 Shanghai Fosun Pharmaceutical Recent Development
11.17 Ingenus
11.17.1 Ingenus Company Detail
11.17.2 Ingenus Business Overview
11.17.3 Ingenus Metastatic Cancer Drug Introduction
11.17.4 Ingenus Revenue in Metastatic Cancer Drug Business (2019-2024)
11.17.5 Ingenus Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Metastatic Cancer Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Trastuzumab
Table 3. Key Players of Pertuzumab
Table 4. Global Metastatic Cancer Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Metastatic Cancer Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Metastatic Cancer Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Metastatic Cancer Drug Market Share by Region (2019-2024)
Table 8. Global Metastatic Cancer Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Metastatic Cancer Drug Market Share by Region (2025-2030)
Table 10. Metastatic Cancer Drug Market Trends
Table 11. Metastatic Cancer Drug Market Drivers
Table 12. Metastatic Cancer Drug Market Challenges
Table 13. Metastatic Cancer Drug Market Restraints
Table 14. Global Metastatic Cancer Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Metastatic Cancer Drug Market Share by Players (2019-2024)
Table 16. Global Top Metastatic Cancer Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2023)
Table 17. Ranking of Global Top Metastatic Cancer Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Metastatic Cancer Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Metastatic Cancer Drug Product Solution and Service
Table 21. Date of Enter into Metastatic Cancer Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Metastatic Cancer Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Metastatic Cancer Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Metastatic Cancer Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Metastatic Cancer Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Metastatic Cancer Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Metastatic Cancer Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Metastatic Cancer Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Metastatic Cancer Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Metastatic Cancer Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Metastatic Cancer Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Metastatic Cancer Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. AstraZeneca Company Detail
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca Metastatic Cancer Drug Product
Table 49. AstraZeneca Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Merck Company Detail
Table 52. Merck Business Overview
Table 53. Merck Metastatic Cancer Drug Product
Table 54. Merck Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 55. Merck Recent Development
Table 56. Pfizer Company Detail
Table 57. Pfizer Business Overview
Table 58. Pfizer Metastatic Cancer Drug Product
Table 59. Pfizer Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Celgene Company Detail
Table 62. Celgene Business Overview
Table 63. Celgene Metastatic Cancer Drug Product
Table 64. Celgene Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 65. Celgene Recent Development
Table 66. AKRON Company Detail
Table 67. AKRON Business Overview
Table 68. AKRON Metastatic Cancer Drug Product
Table 69. AKRON Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 70. AKRON Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Metastatic Cancer Drug Product
Table 74. Novartis Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Galen Company Detail
Table 77. Galen Business Overview
Table 78. Galen Metastatic Cancer Drug Product
Table 79. Galen Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 80. Galen Recent Development
Table 81. Pacira BioSciences Company Detail
Table 82. Pacira BioSciences Business Overview
Table 83. Pacira BioSciences Metastatic Cancer Drug Product
Table 84. Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 85. Pacira BioSciences Recent Development
Table 86. Johnson & Johnson Company Detail
Table 87. Johnson & Johnson Business Overview
Table 88. Johnson & Johnson Metastatic Cancer Drug Product
Table 89. Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 90. Johnson & Johnson Recent Development
Table 91. Fresenius Kabi AG Company Detail
Table 92. Fresenius Kabi AG Business Overview
Table 93. Fresenius Kabi AG Metastatic Cancer Drug Product
Table 94. Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 95. Fresenius Kabi AG Recent Development
Table 96. Spectrum Pharmaceuticals Company Detail
Table 97. Spectrum Pharmaceuticals Business Overview
Table 98. Spectrum Pharmaceuticals Metastatic Cancer Drug Product
Table 99. Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 100. Spectrum Pharmaceuticals Recent Development
Table 101. Takeda Pharmaceutical Company Detail
Table 102. Takeda Pharmaceutical Business Overview
Table 103. Takeda Pharmaceutical Metastatic Cancer Drug Product
Table 104. Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 105. Takeda Pharmaceutical Recent Development
Table 106. Teva Pharmaceutical Industries Company Detail
Table 107. Teva Pharmaceutical Industries Business Overview
Table 108. Teva Pharmaceutical Industries Metastatic Cancer Drug Product
Table 109. Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 110. Teva Pharmaceutical Industries Recent Development
Table 111. Cipla Company Detail
Table 112. Cipla Business Overview
Table 113. Cipla Metastatic Cancer Drug Product
Table 114. Cipla Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 115. Cipla Recent Development
Table 116. Sun Pharmaceutical Industries Company Detail
Table 117. Sun Pharmaceutical Industries Business Overview
Table 118. Sun Pharmaceutical Industries Metastatic Cancer Drug Product
Table 119. Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 120. Sun Pharmaceutical Industries Recent Development
Table 121. Shanghai Fosun Pharmaceutical Company Detail
Table 122. Shanghai Fosun Pharmaceutical Business Overview
Table 123. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Product
Table 124. Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 125. Shanghai Fosun Pharmaceutical Recent Development
Table 126. Ingenus Company Detail
Table 127. Ingenus Business Overview
Table 128. Ingenus Metastatic Cancer Drug Product
Table 129. Ingenus Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 130. Ingenus Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metastatic Cancer Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Metastatic Cancer Drug Market Share by Type: 2023 VS 2030
Figure 3. Trastuzumab Features
Figure 4. Pertuzumab Features
Figure 5. Global Metastatic Cancer Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Metastatic Cancer Drug Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Metastatic Cancer Drug Report Years Considered
Figure 10. Global Metastatic Cancer Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Metastatic Cancer Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Metastatic Cancer Drug Market Share by Region: 2023 VS 2030
Figure 13. Global Metastatic Cancer Drug Market Share by Players in 2023
Figure 14. Global Top Metastatic Cancer Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Metastatic Cancer Drug Revenue in 2023
Figure 16. North America Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 18. United States Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 22. Germany Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Metastatic Cancer Drug Market Share by Region (2019-2030)
Figure 30. China Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 38. Mexico Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 42. Turkey Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. AstraZeneca Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 45. Merck Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 46. Pfizer Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 47. Celgene Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 48. AKRON Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 50. Galen Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 51. Pacira BioSciences Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 52. Johnson & Johnson Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 53. Fresenius Kabi AG Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 54. Spectrum Pharmaceuticals Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 55. Takeda Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 56. Teva Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 57. Cipla Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 58. Sun Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 59. Shanghai Fosun Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 60. Ingenus Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Metastatic Cancer Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Trastuzumab
Table 3. Key Players of Pertuzumab
Table 4. Global Metastatic Cancer Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Metastatic Cancer Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Metastatic Cancer Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Metastatic Cancer Drug Market Share by Region (2019-2024)
Table 8. Global Metastatic Cancer Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Metastatic Cancer Drug Market Share by Region (2025-2030)
Table 10. Metastatic Cancer Drug Market Trends
Table 11. Metastatic Cancer Drug Market Drivers
Table 12. Metastatic Cancer Drug Market Challenges
Table 13. Metastatic Cancer Drug Market Restraints
Table 14. Global Metastatic Cancer Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Metastatic Cancer Drug Market Share by Players (2019-2024)
Table 16. Global Top Metastatic Cancer Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2023)
Table 17. Ranking of Global Top Metastatic Cancer Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Metastatic Cancer Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Metastatic Cancer Drug Product Solution and Service
Table 21. Date of Enter into Metastatic Cancer Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Metastatic Cancer Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Metastatic Cancer Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Metastatic Cancer Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Metastatic Cancer Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Metastatic Cancer Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Metastatic Cancer Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Metastatic Cancer Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Metastatic Cancer Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Metastatic Cancer Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Metastatic Cancer Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Metastatic Cancer Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Metastatic Cancer Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Metastatic Cancer Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Metastatic Cancer Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. AstraZeneca Company Detail
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca Metastatic Cancer Drug Product
Table 49. AstraZeneca Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Merck Company Detail
Table 52. Merck Business Overview
Table 53. Merck Metastatic Cancer Drug Product
Table 54. Merck Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 55. Merck Recent Development
Table 56. Pfizer Company Detail
Table 57. Pfizer Business Overview
Table 58. Pfizer Metastatic Cancer Drug Product
Table 59. Pfizer Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Celgene Company Detail
Table 62. Celgene Business Overview
Table 63. Celgene Metastatic Cancer Drug Product
Table 64. Celgene Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 65. Celgene Recent Development
Table 66. AKRON Company Detail
Table 67. AKRON Business Overview
Table 68. AKRON Metastatic Cancer Drug Product
Table 69. AKRON Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 70. AKRON Recent Development
Table 71. Novartis Company Detail
Table 72. Novartis Business Overview
Table 73. Novartis Metastatic Cancer Drug Product
Table 74. Novartis Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Galen Company Detail
Table 77. Galen Business Overview
Table 78. Galen Metastatic Cancer Drug Product
Table 79. Galen Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 80. Galen Recent Development
Table 81. Pacira BioSciences Company Detail
Table 82. Pacira BioSciences Business Overview
Table 83. Pacira BioSciences Metastatic Cancer Drug Product
Table 84. Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 85. Pacira BioSciences Recent Development
Table 86. Johnson & Johnson Company Detail
Table 87. Johnson & Johnson Business Overview
Table 88. Johnson & Johnson Metastatic Cancer Drug Product
Table 89. Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 90. Johnson & Johnson Recent Development
Table 91. Fresenius Kabi AG Company Detail
Table 92. Fresenius Kabi AG Business Overview
Table 93. Fresenius Kabi AG Metastatic Cancer Drug Product
Table 94. Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 95. Fresenius Kabi AG Recent Development
Table 96. Spectrum Pharmaceuticals Company Detail
Table 97. Spectrum Pharmaceuticals Business Overview
Table 98. Spectrum Pharmaceuticals Metastatic Cancer Drug Product
Table 99. Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 100. Spectrum Pharmaceuticals Recent Development
Table 101. Takeda Pharmaceutical Company Detail
Table 102. Takeda Pharmaceutical Business Overview
Table 103. Takeda Pharmaceutical Metastatic Cancer Drug Product
Table 104. Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 105. Takeda Pharmaceutical Recent Development
Table 106. Teva Pharmaceutical Industries Company Detail
Table 107. Teva Pharmaceutical Industries Business Overview
Table 108. Teva Pharmaceutical Industries Metastatic Cancer Drug Product
Table 109. Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 110. Teva Pharmaceutical Industries Recent Development
Table 111. Cipla Company Detail
Table 112. Cipla Business Overview
Table 113. Cipla Metastatic Cancer Drug Product
Table 114. Cipla Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 115. Cipla Recent Development
Table 116. Sun Pharmaceutical Industries Company Detail
Table 117. Sun Pharmaceutical Industries Business Overview
Table 118. Sun Pharmaceutical Industries Metastatic Cancer Drug Product
Table 119. Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 120. Sun Pharmaceutical Industries Recent Development
Table 121. Shanghai Fosun Pharmaceutical Company Detail
Table 122. Shanghai Fosun Pharmaceutical Business Overview
Table 123. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Product
Table 124. Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 125. Shanghai Fosun Pharmaceutical Recent Development
Table 126. Ingenus Company Detail
Table 127. Ingenus Business Overview
Table 128. Ingenus Metastatic Cancer Drug Product
Table 129. Ingenus Revenue in Metastatic Cancer Drug Business (2019-2024) & (US$ Million)
Table 130. Ingenus Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metastatic Cancer Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Metastatic Cancer Drug Market Share by Type: 2023 VS 2030
Figure 3. Trastuzumab Features
Figure 4. Pertuzumab Features
Figure 5. Global Metastatic Cancer Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Metastatic Cancer Drug Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Metastatic Cancer Drug Report Years Considered
Figure 10. Global Metastatic Cancer Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Metastatic Cancer Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Metastatic Cancer Drug Market Share by Region: 2023 VS 2030
Figure 13. Global Metastatic Cancer Drug Market Share by Players in 2023
Figure 14. Global Top Metastatic Cancer Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Metastatic Cancer Drug Revenue in 2023
Figure 16. North America Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 18. United States Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 22. Germany Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Metastatic Cancer Drug Market Share by Region (2019-2030)
Figure 30. China Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 38. Mexico Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Metastatic Cancer Drug Market Share by Country (2019-2030)
Figure 42. Turkey Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Metastatic Cancer Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. AstraZeneca Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 45. Merck Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 46. Pfizer Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 47. Celgene Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 48. AKRON Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 50. Galen Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 51. Pacira BioSciences Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 52. Johnson & Johnson Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 53. Fresenius Kabi AG Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 54. Spectrum Pharmaceuticals Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 55. Takeda Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 56. Teva Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 57. Cipla Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 58. Sun Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 59. Shanghai Fosun Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 60. Ingenus Revenue Growth Rate in Metastatic Cancer Drug Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Camelina Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Bentgrass Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Barley Seeds - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 11, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232